Epithalon Dosage Guide: Reported Ranges, Reconstitution & Evidence

Epithalon at a glance

What it is

Epithalon (Epitalon, AEDG), the synthetic tetrapeptide Ala-Glu-Asp-Gly, modeled on the pineal extract epithalamin

Researched for

Telomerase activity, cellular aging and pineal/circadian regulation in cell and animal models

Commonly reported range

Community examples of roughly 5-10 mg per day for short courses (no established human dose)

Route reported

Subcutaneous injection in most reported protocols

Reported frequency

Once daily during a course

Reported cycle

Community examples of 10-20 day courses, repeated once or twice a year

Plasma half-life

Very short - minutes; no established human pharmacokinetic profile

Regulatory status

Not FDA-approved and not an approved medicine anywhere; research use only

Reported ranges from research/community — examples, not recommendations.

What it is / mechanism

Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed from epithalamin, a pineal-gland extract studied by Vladimir Khavinson's group in St Petersburg. The proposed mechanism belongs to the Khavinson 'peptide bioregulator' framework, in which short peptides are described as binding directly to specific DNA sequences in gene promoter regions and thereby modulating transcription. In this model Epithalon is reported to induce expression of the telomerase catalytic subunit (hTERT), increasing telomerase activity and, in cell culture, telomere elongation. It has also been described as influencing melatonin secretion and circadian regulation via pineal activity, and as having antioxidant effects in animal models. It is worth stating plainly that the direct DNA-binding mechanism proposed for peptide bioregulators is not a broadly accepted model in mainstream molecular biology, and the supporting work comes overwhelmingly from a single research tradition.

Researched effects

In cell-culture research Epithalon has been associated with induction of telomerase, telomere elongation, and extension of fibroblast replicative capacity beyond the usual Hayflick limit. In rodent studies chronic administration has been reported to extend mean lifespan and reduce spontaneous tumour incidence. These are reported findings in cells and animals. The critical limitation, which any honest summary must state, is that there is no peer-reviewed, independently replicated controlled trial in humans demonstrating that Epithalon meaningfully lengthens telomeres or extends lifespan - no completed human trial has measured telomere length before and after administration under controlled conditions. Nothing here is a promise of efficacy or a personal recommendation.

Dosage — reported ranges (overview)

The figures below are examples of what has been reported in research and community settings, not a recommendation. Community protocols commonly describe 5 to 10 mg per day by subcutaneous injection for a course of 10 to 20 days, repeated once or twice a year rather than taken continuously - the cyclical pattern reflects how the original Russian studies were structured rather than any established pharmacological requirement. There is no established human dose, no approved label, and no controlled trial defining a dose or a course length. Readers should treat confident-sounding protocol figures circulating online with caution, since they are not traceable to controlled human data.

A printable protocol sheet with a reconstitution reference and an injection log comes with All-Access Lifetime.

Reconstitution — bac-water math

Epithalon is dosed in milligrams, so reconstitution is a concentration calculation. Add bacteriostatic water to the lyophilized vial and the concentration is the vial's total mg divided by the water volume in mL. On a U-100 insulin syringe, 100 units equals 1 mL, so units to draw = dose (mg) / concentration (mg/mL) x 100. Worked example: a 50 mg vial reconstituted with 2 mL of bacteriostatic water gives 25 mg/mL; a 10 mg example is then 10 / 25 = 0.4 mL, which is 40 units on a U-100 syringe. Epithalon is often supplied in larger vials intended to cover a full multi-day course, so check the vial's total mg before calculating. This is concentration math only, not a personal dose.

This is concentration math, not a dose recommendation.

Injection / administration basics

Reported protocols describe subcutaneous injection using a U-100 insulin syringe, once daily for the duration of a short course, with site rotation. General handling concepts - sterile technique, site rotation, consistent daily timing - are covered here as general information; the detailed workflow comes with All-Access Lifetime, which includes the printable protocol sheet and injection log for every compound. This is general educational information, not a personal administration protocol; a qualified professional should guide any actual use.

Half-life & frequency rationale

Epithalon is a very small tetrapeptide and is cleared from plasma rapidly, on the order of minutes; no established human pharmacokinetic profile has been published. As with other short peptide bioregulators, reported effects are attributed to downstream transcriptional changes rather than sustained plasma levels - which is the stated rationale for short daily courses. It should be noted that this rationale is an inference from the proposed mechanism rather than a conclusion from human PK data.

Stacking — overview

Epithalon is commonly discussed alongside other Khavinson-family peptide bioregulators such as Thymalin and Cartalax, and with GHK-Cu in general longevity and tissue-remodeling discussion. There is no controlled evidence for any of these combinations; they reflect reported pairings, not recommendations.

For how combinations are grouped by research context, the named blends, and why a pre-mixed blend vial cannot be calculated from its total milligrams, see the peptide stacks guide.

Storage & handling

• Lyophilized (unreconstituted) vials are typically stored refrigerated and protected from light; the sealed powder is generally described as stable at room temperature for short periods before use.
• After reconstitution, keep refrigerated at about 2-8 C, protect from light, and use within a few weeks; do not freeze and avoid shaking. Larger course-sized vials are held reconstituted across a course, so storage conditions matter more here than for single-use amounts.

Evidence File

Epithalon Evidence File: An Orphan-Drug Record, Microgram Human Doses, and a Corrected 2025 Replication

Epithalon carries one of the most confidently cited evidence bases in the peptide market and one of the least examined. This file goes to the primary records instead of the summaries: a regulatory file held by a national agency, the two published human studies and what they actually specified, the most-cited mouse experiment read line by line, and the 2025 independent cell-culture study together with the publishing history that followed it. Every registry search is named so a reader can repeat it, and each circulating figure is traced back to the paper it came from before it is graded. Where the record is deflationary, this file says so first rather than last.

• FDA orphan record 312010: Epitalon, retinitis pigmentosa, designated then withdrawn
• Published human doses were 5 micrograms per eye and 0.5 mg per day sublingual
• Flagship mouse study: mean lifespan and total tumour incidence both unchanged
• The 2025 independent study was corrected in November 2025, all three figures replaced

Sourcing File

Epithalon Sourcing File: Two Molecules, One Exact Mass, and the Certificate That Cannot Tell Them Apart

Generic certificate advice does not carry over to this peptide. Its four residues can be rearranged and re-linked into molecules that share its formula and its exact mass, so the identity line most certificates print settles less than it appears to; its side-chain chemistry breaks a detection method that certificates routinely quote; and its charge profile pushes the usual salt-correction rule of thumb in the wrong direction. This file works through the registry identifiers, the three compound-specific mislabelling routes, the counterion arithmetic with the numbers shown, and a worked line-by-line read of a certificate.

• EADG shares the formula and the exact mass, so mass alone cannot exclude it
• No aromatic residue, so a 280 nm purity chromatogram cannot detect this peptide
• A mono-TFA salt puts a 77.4 percent floor under net peptide content
• CAS 307297-39-8 is the peptide; 64082-79-7 is an extract number PubChem merged in

Benefit & Outcome Review

Epithalon Benefit and Outcome Review: Seven Claims Graded, With Human Evidence Kept Separate

Each claim made for Epithalon is taken one at a time here, and human, animal and cell-culture evidence are listed separately and never added together. Where a claim has no human evidence, that is the first line of the entry rather than a footnote at the end. The review also collects the things this literature reports that promotional summaries leave out: which subjects failed to respond, how quickly measured effects reversed after treatment stopped, where two studies point in opposite directions, and which widely quoted outcome numbers were generated with a different substance entirely.

• The 28 percent mortality figure belongs to a bovine pineal extract, not this peptide
• Melatonin effects are reported only where melatonin was already low
• Monkey glucose values drifted back toward baseline a month after stopping
• No located study has measured telomere length in a treated animal or person

Guide FAQ

Quick answers about guide scope, access, and educational use context.